TheraNovis

About Us

An AI-powered end-to-end precision cancer diagnostics platform.

Our Mission

Tumor Microenvironment (TME): A Key Driver in the Immunotherapy & ADC Era

Spatial Context–Driven Response Prediction

Paradigm Shift

Shift Toward IO & ADC Therapies

Predictive Challenges

Beyond Single-Biomarker Prediction

Growing Market Demand

Rising Demand for TME-Based Spatial Biology

TheraNovis Lab
Growth Journey

Validation → Scale-Up → Commercialization

2021

Company Founded

Beginning of Spatial Biology Innovation

2023

Phenoview Launched

Launch of Phenoview (now AstraTSA) TIPS Program Selection Total KRW 2.56B Funding Raised

2024

Accelerated Growth

KRW 11B Funding Secured Strategic Partnerships Expanded

Clinical, Research & Commercialization Expertise

Founded by Asan Medical Center Faculty Experts in Spatial Biology & Fluorescence Imaging

16 M.S./Ph.D. Scientists in Biomedical R&D Business Development & Commercialization Experts Leading Contributions to Multiplex IHC Research

Sang-Yeob Kim

Sang-Yeob Kim

Chief Executive Officer (CEO)

Director, Bioimaging Center Expert in Optical Imaging Analysis 120+ SCI(E) Publications